Bioenergetics

Biomarker discovery requires high confidence identification of biomarker candidates with simultaneous quantitation information to indicate which proteins are changing to a statistically relevant degree in response to disease. The discovery of molecular biomarkers has developed new strategies starting from the initial steps. In the first stage of biomarker discovery events, research depends upon mass spectrometry techniques to perform unbiased, semi quantitative analysis of differences between diseased and healthy states. Due to the high false positive rate, the list of biomarker candidates generated in the discovery stage must be further verified through additional more targeted and quantitative mass spectrometry techniques, such as immune affinity peptide enrichment.

Related Conferences: 12th Euro Global Summit on Cancer Therapy, September 26-28, 2016 UK; 6th International Conference on Genomics & Pharmacogenomics, September 22-24, 2016, Germany; 7th International Conference on Biomarkers & Clinical Research, November 28-30, 2016, USA; 6th International Conference & Expo on Proteomics March 29-30, 2016, USA; Cancer Diagnostics Conference & Expo June 13-15, 2016 Italy; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016 USA; 2ndBiomarkers Conference September 19-20, 2016 UK; 18th International Conference on Biomarkers and Clinical Medicine, March 24-25, 2016 Spain; 23rd International Molecular Med TRI-CON March 06-11, 2016 USA; Circulating Biomarkers World Congress March 21-22, 2016 USA.

  • prognostic molecular markers
  • Glioblastoma molecular markers
  • Thyroid cancer molecular markers
  • Prostate cancer molecular markers
  • Molecular markers plants
  • Molecular markers breast cancer

Related Conference of Bioenergetics

Bioenergetics Conference Speakers